FDA Expands Patient Access to Pancreatic Cancer Drug That Doubled Survival in Trial
The Food and Drug Administration announced it will broaden eligibility for a pancreatic cancer therapy that nearly doubled survival rates for advanced‑stage patients in a large clinical study. The move aims to make the treatment available to a wider group of patients while further data are gathered.
Advertisement: Article Inline